Drug intelligence / Profile preview

PEEL-224 + 5-fluorouracil + leucovorin + bevacizumab

Development stage: Unknown
Lead developer: PEEL Therapeutics
Modality: Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

PEEL-224 + FOLF + B is an investigational combination therapy consisting of PEEL-224, 5-fluorouracil (5-FU), leucovorin (folinic acid), and bevacizumab. Developed by Peel Therapeutics, this regimen is primarily being evaluated for the treatment of advanced solid tumors, with a focus on colorectal cancer and sarcomas. PEEL-224 is a pegylated topoisomerase I (TOP1) inhibitor, a polymer-drug conjugate derived from camptothecin designed to enhance the delivery and efficacy of the TOP1 inhibitor while minimizing systemic toxicities like neutropenia and diarrhea. In this combination, PEEL-224 acts as the cytotoxic TOP1 inhibitor, 5-FU and leucovorin provide thymidylate synthase inhibition, and bevacizumab targets vascular endothelial growth factor (VEGF) to inhibit angiogenesis. The combination is currently undergoing Phase 1 clinical trials to determine safety, tolerability, and preliminary efficacy.

Other names: PEEL-224 + FOLF + BPEEL-224 in combination with FOLFPBPEEL224 in combination with FOLFPBPEEL 224 in combination with FOLFPBPEEL-224 + 5-FU + Leucovorin + Bevacizumab

Targets

VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on PEEL-224 + 5-fluorouracil + leucovorin + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEEL-224 + 5-fluorouracil + leucovorin + bevacizumab.

Explore the full profile